SCHEMBL1000103

SCHEMBL1000103

COc1cc(Br)cc(OC)c1N

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.58
NPSR1 Q6W5P4 2/20 0.58
POLB P06746 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
APP P05067 3/20 0.44
ERN1 O75460 1/20 0.44
ALOX15 P16050 1/20 0.44
ALOX12 P18054 1/20 0.44
PIM1 P11309 1/20 0.42
NQO2 P16083 2/20 0.41
EP300 Q09472 1/20 0.41
ALDH1A1 P00352 4/20 0.40
GAA P10253 2/20 0.40
CYP3A4 P08684 2/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
PRNP P04156 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5946197 0.88 MAPT (0.57) MAPTNPSR1POLBL3MBTL1APP
SCHEMBL2498762 0.88 MAPT (0.52) MAPTNPSR1POLBL3MBTL1APP
SCHEMBL31211203 0.88 MAPT (0.57) MAPTNPSR1POLBL3MBTL1APP
SCHEMBL289511 0.86 MAPT (0.50) MAPTNPSR1POLBL3MBTL1APP
SCHEMBL934101 0.84 MAPT (0.48) MAPTNPSR1POLBL3MBTL1APP
SCHEMBL27801325 0.84 MAPT (0.48) MAPTNPSR1POLBL3MBTL1APP
SCHEMBL22118208 0.84 MAPT (0.48) MAPTNPSR1POLBL3MBTL1APP
Bromide SCHEMBL15328872 0.84 MAPT (0.48) MAPTNPSR1POLBL3MBTL1APP
SCHEMBL31506852 0.84 MAPT (0.48) MAPTNPSR1POLBL3MBTL1APP
Bromide SCHEMBL15880338 0.83 MAPT (0.47) MAPTNPSR1POLBL3MBTL1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117209465-A Flavonoid derivatives, preparation method and application 程鑫 2023-12-12 CN claimed
EP-0280975-A1 Processes for the production of substituted benzaldehydes, and intermediate products obtained by these processes F. HOFFMANN-LA ROCHE AG (CH) 1988-09-07 EP claimed
EP-4262788-B1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2026-01-21 EP disclosed
EP-4673442-A1 PHOTOSWITCHABLE COMPOUNDS AND AFFINITY LIGANDS, AND THEIR USE FOR THE OPTICAL CONTROL OF AFFINITY MATRICES AFC Innovations GmbH (DE) 2026-01-07 EP disclosed
US-12503477-B2 Colony stimulating factor-1 receptor (CSF-1R) inhibitors GENZYME CORPORATION 2025-12-23 US disclosed
WO-2025136811-A1 CHEMICAL COMPOUNDS AND USES THEREOF IDEAYA BIOSCIENCES, INC. (US) 2025-06-26 WO disclosed
CN-119912402-A FTO inhibitor and preparation method and application thereof 中国科学院上海药物研究所 2025-05-02 CN disclosed
WO-2024180254-A1 PHOTOSWITCHABLE COMPOUNDS AND AFFINITY LIGANDS, AND THEIR USE FOR THE OPTICAL CONTROL OF AFFINITY MATRICES AFC INNOVATIONS GMBH (DE) 2024-09-06 WO disclosed
US-20240217991-A1 COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS GENZYME CORPORATION (US) 2024-07-04 US disclosed
US-20240101555-A1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2024-03-28 US disclosed
CN-117209465-A Flavonoid derivatives, preparation method and application 程鑫 2023-12-12 CN disclosed
US-6706703-B2 BIS(5-ARYL-2-PYRIDYL) COMPOUND HAVING EXCELLENT IMMUNOGLOBULIN (IGE) ANTIBODY PRODUCTION INHIBITING ACTIVITY, USEFUL FOR THE PREVENTION OR TREATMENT OF ALLERGIC IMMUNE DISEASES KOWA CO., LTD. (JP) 2004-03-16 US disclosed
US-20040010147-A1 Cyclic amine compounds and pharmaceutical composition containing the same KOWA CO., LTD. (JP) 2004-01-15 US disclosed
WO-2003086397-A1 MEDICINE FOR TREATING CANCER KOWA CO., LTD. (JP) 2003-10-23 WO disclosed
US-6605620-B1 Such as 4-(N-(4-Methoxyphenyl)-N-(3-(3,4,5-trimethoxy-phenyl)-benzoylamino)-1-((2 -(3,4,5-trimethoxyphenyl)pyridin-4-yl)-methyl)piperidine; treatment and prevention of cell adhesion or infiltration KOWA CO., LTD. (JP) 2003-08-12 US disclosed
US-20030027814-A1 Bis(5-aryl-2-pyridyl) derivatives KOWA CO., LTD. (JP) 2003-02-06 US disclosed
US-6498169-B1 CELL ADHESION AND INFILTRATION INHIBITORS; ANTIASTHMATICS, ANTIALLERGENS, ANTIRHEUMATICS, ANTIARTERIOSCLEROTICS, ANTIINFLAMMATORIES AND ANTI SJOGREN'S SYNDROME AGENTS KOWA CO., LTD. (JP) 2002-12-24 US disclosed
US-6395753-B1 ANTIHISTAMINES, ANTIALLERGENS, ANTIARTHRITIC AGENTS KOWA CO., LTD. (JP) 2002-05-28 US disclosed
EP-0280975-B1 PROCESSES FOR THE PRODUCTION OF SUBSTITUTED BENZALDEHYDES, AND INTERMEDIATE PRODUCTS OBTAINED BY THESE PROCESSES F. HOFFMANN-LA ROCHE AG (CH) 1992-07-08 EP disclosed
EP-0280975-A1 Processes for the production of substituted benzaldehydes, and intermediate products obtained by these processes F. HOFFMANN-LA ROCHE AG (CH) 1988-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030027814-A1 Bis(5-aryl-2-pyridyl) derivatives AHR, PAH, H1-0 MAPT 3926/4885NPSR1 363/4885POLB 1554/4885
US-20240217991-A1 COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS CSF1R, CSF3R, IL1RN MAPT 2666/4885NPSR1 139/4885POLB 3273/4885
US-20040010147-A1 Cyclic amine compounds and pharmaceutical composition containing the same HRH3, HRH4, CNKSR1 MAPT 3570/4885NPSR1 128/4885POLB 2431/4885
US-12503477-B2 Colony stimulating factor-1 receptor (CSF-1R) inhibitors CSF1R, CSF3R, IL1RN MAPT 1811/4885NPSR1 187/4885POLB 4121/4885
US-20240101555-A1 UREA OREXIN RECEPTOR AGONISTS HCRTR1, HCRTR2, UTS2R MAPT 307/4885NPSR1 14/4885POLB 4539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.